{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:33:51Z","timestamp":1793705631614,"version":"4.5.1"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Live attenuated measles-mumps-rubella (MMR) and varicella vaccines are recommended for immunocompetent people with multiple sclerosis (MS) lacking immunity. However, concerns about postvaccination relapses may contribute to vaccine hesitancy, and robust data addressing this risk remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether the risk of MS relapse within 1 year after MMR or varicella vaccination is not unacceptably worse than risk after no such vaccination based on a predefined noninferiority margin.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used prospectively collected data from July 2016 to October 2024 for people with MS at a tertiary MS center in Barcelona, Spain, who received at least 1 dose of live attenuated MMR and\/or varicella vaccine due to serologic susceptibility. Vaccinated patients were matched 1:2 with unvaccinated control individuals with MS by sex, age, and epoch of first demyelinating event.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Live attenuated MMR and\/or varicella vaccine.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were relapse count and time to first relapse within 1 year of time 0, analyzed using Poisson and Cox proportional hazards regression models with inverse probability weighting based on a propensity score including treatment category, Expanded Disability Status Scale score, and annualized relapse rate in the prior year. Noninferiority was predefined as an annualized relapse rate ratio with an upper bound of the 95% CI less than 1.4.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 369 people with MS were included, of whom 123 were vaccinated (mean [SD] age, 28.75 [8.72] years; 85 females [69.1%]) and matched to 246 unvaccinated controls (mean [SD] age, 28.66 [8.60] years; 170 females [69.1%]). Overall, 36 relapse events were observed (15 [41.7%] among vaccinated patients and 21 [58.3%] among unvaccinated controls). In the weighted Poisson model, although relapse incidence was not significantly different between vaccinated and unvaccinated individuals (incidence rate ratio, 0.52; 95% CI, 0.23-1.06), the noninferiority criterion was met. Similarly, weighted Cox proportional hazards regression models showed no difference in hazard of relapse between groups (hazard ratio [HR], 0.55; 95% CI, 0.25-1.17) but the noninferiority criterion was met. Sensitivity and exploratory analyses, including time-dependent adjustment for postbaseline treatment exposure (HR, 0.60; 95% CI, 0.27-1.33), restriction to the high-risk period (n\u2009=\u200915 events), and comparisons of magnetic resonance imaging before (n\u2009=\u200943 events) and after (n\u2009=\u200921 events) exposure in vaccinated patients, revealed findings consistent with those of the primary analysis.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of nonimmunosuppressed people with MS, vaccination with live attenuated MMR or varicella vaccine was not associated with increased risk of postvaccination relapse. The results support the administration of these vaccines when indicated and may help reassure clinicians and patients, reducing vaccine hesitancy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.13742","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:30:28Z","timestamp":1779291028000},"page":"e2613742","source":"Crossref","is-referenced-by-count":3,"title":["Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity"],"prefix":"10.1001","volume":"9","author":[{"given":"Ren\u00e9","family":"Carvajal","sequence":"first","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia, Vic, Catalonia, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia, Manresa, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ponzano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Tur","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Esperalba","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Cobo-Calvo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Borras-Bemejo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Ari\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bollo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Castill\u00f3","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Comabella","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hern\u00e1ndez-Soria","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Midaglia","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Mongay-Ochoa","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Pappolla","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alejandro","family":"Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Rodrigo-Pend\u00e1s","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breog\u00e1n","family":"Rodr\u00edguez-Acevedo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"R\u00edo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Vidal-Jordana","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Vilaseca","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Zabalza","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"Istituti di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia, Vic, Catalonia, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia, Manresa, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tintor\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia, Vic, Catalonia, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia, Manresa, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Otero-Romero","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"7","key":"zoi260404r1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/13524585251318513","article-title":"Vaccination in multiple sclerosis: tackling challenges and paving the way for effective immunization.","volume":"31","author":"Carvajal","year":"2025","journal-title":"Mult Scler"},{"issue":"8","key":"zoi260404r2","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/13524585231168043","article-title":"ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs.","volume":"29","author":"Otero-Romero","year":"2023","journal-title":"Mult Scler"},{"issue":"2","key":"zoi260404r3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies.","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"7","key":"zoi260404r4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458518823940","article-title":"The role of infections in multiple sclerosis.","volume":"25","author":"Marrodan","year":"2019","journal-title":"Mult Scler"},{"issue":"4","key":"zoi260404r5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ana.27026","article-title":"Hospital-treated infections and risk of disability worsening in multiple sclerosis.","volume":"96","author":"Hu","year":"2024","journal-title":"Ann Neurol"},{"issue":"6","key":"zoi260404r6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination.","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract Neurol"},{"issue":"2","key":"zoi260404r7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments.","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"zoi260404r8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"issue":"11-12","key":"zoi260404r9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/13524585231204126","article-title":"Rethinking vaccination in multiple sclerosis: the way forward.","volume":"29","author":"Reyes","year":"2023","journal-title":"Mult Scler"},{"issue":"10","key":"zoi260404r10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archneurol.2011.131","article-title":"Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.","volume":"68","author":"Farez","year":"2011","journal-title":"Arch Neurol"},{"issue":"2","key":"zoi260404r11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/13524585241305956","article-title":"Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: a complex decision.","volume":"31","author":"Correale","year":"2025","journal-title":"Mult Scler"},{"key":"zoi260404r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103236","article-title":"Vaccine hesitancy among people with multiple sclerosis.","volume":"56","author":"Yap","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"10489","key":"zoi260404r13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)00675-0","article-title":"Measles: the urgent need for global immunisation and preparedness.","volume":"405","author":"Kuppalli","year":"2025","journal-title":"Lancet"},{"issue":"24","key":"zoi260404r14","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1056\/NEJMra2504516","article-title":"Measles 2025.","volume":"393","author":"Do","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260404r15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1177\/13524585211069068","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop review. April 2021.","volume":"28","author":"Tur","year":"2022","journal-title":"Mult Scler"},{"issue":"20","key":"zoi260404r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"zoi260404r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.6345","article-title":"Vaccine safety and immunogenicity in patients with multiple sclerosis treated with natalizumab.","volume":"7","author":"Carvajal","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"14","key":"zoi260404r19","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1177\/13524585231200303","article-title":"A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.","volume":"29","author":"Carvajal","year":"2023","journal-title":"Mult Scler"},{"issue":"7","key":"zoi260404r20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination.","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"25","key":"zoi260404r21","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1016\/j.vaccine.2021.02.074","article-title":"Correlation of protection against varicella in a randomized phase III varicella-containing vaccine efficacy trial in healthy infants.","volume":"39","author":"Habib","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"zoi260404r22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"Pt 7","key":"zoi260404r23","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis.","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"key":"zoi260404r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101302","article-title":"The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study.","volume":"53","author":"Tur","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"14","key":"zoi260404r25","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1177\/13524585211006372","article-title":"Multiple sclerosis: is there a risk of worsening after yellow fever vaccination?","volume":"27","author":"Papeix","year":"2021","journal-title":"Mult Scler"},{"issue":"3","key":"zoi260404r26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/1744666X.2021.1886924","article-title":"Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment.","volume":"17","author":"Otero-Romero","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"zoi260404r27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","article-title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry.","volume":"29","author":"Spelman","year":"2023","journal-title":"Mult Scler"},{"issue":"8","key":"zoi260404r28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis.","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi260404r29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis.","volume":"344","author":"Confavreux","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260404r31","first-page":"454","article-title":"Methodological considerations for observational studies of treatment effectiveness in neurology: a clinician\u2019s guide.","volume":"95","author":"Kalincik","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"zoi260404r32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jech.2002.006361","article-title":"A definition of causal effect for epidemiological research.","volume":"58","author":"Hern\u00e1n","year":"2004","journal-title":"J Epidemiol Community Health"},{"issue":"12","key":"zoi260404r33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial\u2014the TARGET statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"issue":"7","key":"zoi260404r34","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis: systematic review and meta-analysis.","volume":"258","author":"Farez","year":"2011","journal-title":"J Neurol"},{"issue":"11-12","key":"zoi260404r36","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1177\/13524585231204121","article-title":"Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: a case series.","volume":"29","author":"Lapucci","year":"2023","journal-title":"Mult Scler"},{"key":"zoi260404r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104793","article-title":"Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: a case series and review of the literature.","volume":"77","author":"Paybast","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"zoi260404r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106285","article-title":"Is it time to consider the live attenuated varicella-zoster virus (VZV) vaccination safe in patients with multiple sclerosis treated with natalizumab? an extension study of the first Iranian experience.","volume":"95","author":"Paybast","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"zoi260404r39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000726","article-title":"Risk of MS relapse after yellow fever vaccination: a self-controlled case series.","volume":"7","author":"Huttner","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"zoi260404r40","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamaneurol.2023.2968","article-title":"Vaccines and the risk of hospitalization for multiple sclerosis flare-ups.","volume":"80","author":"Grimaldi","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"zoi260404r41","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000664","article-title":"Tick-borne encephalitis vaccination in multiple sclerosis: a prospective, multicenter study.","volume":"7","author":"Winkelmann","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"zoi260404r42","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241309806","article-title":"Vaccination coverage and its determinants in patients with multiple sclerosis\u2014a multicenter cross-sectional study.","author":"Schade","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"zoi260404r45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1080\/10543406.2015.1052819","article-title":"Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety.","volume":"26","author":"Li","year":"2016","journal-title":"J Biopharm Stat"},{"issue":"3","key":"zoi260404r46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"zoi260404r16","unstructured":"WMA Declaration of Tokyo\u2014guidelines for physicians concerning torture and other cruel, inhuman or degrading treatment or punishment in relation to detention and imprisonment. World Medical Association. May 19, 2006. Accessed April 24, 2024. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-tokyo-guidelines-for-physicians-concerning-torture-and-other-cruel-inhuman-or-degrading-treatment-or-punishment-in-relation-to-detention-and-imprisonment\/"},{"key":"zoi260404r30","unstructured":"Immunization, vaccines and biologicals: vaccine-preventable diseases (including pipeline vaccines). World Health Organization. Accessed June 30, 2024. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases"},{"key":"zoi260404r35","unstructured":"European Medicines Agency; Science Medicines Health. Tysabri (natalizumab). Accessed July 30, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri#authorisation-details"},{"key":"zoi260404r43","unstructured":"Surveillance report: hepatitis B\u2014annual epidemiological report for 2022. European Centre for Disease Prevention and Control. 2024. Accessed September 12, 2024. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER%20HEPB%202022_0.pdf"},{"key":"zoi260404r44","unstructured":"Measles (rubeola): measles cases and outbreaks. US Centers for Disease Control and Prevention. March 27, 2026. Accessed March 28, 2026. https:\/\/www.cdc.gov\/measles\/data-research\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849165\/carvajal_2026_oi_260404_1778598206.92227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:30:32Z","timestamp":1779291032000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.13742","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}